Loading...
Long‐term efficacy and safety of bosutinib in patients with advanced leukemia following resistance/intolerance to imatinib and other tyrosine kinase inhibitors
Long‐term efficacy and safety of bosutinib (≥4 years follow‐up from last enrolled patient) were evaluated in an ongoing phase 1/2 study in the advanced leukemia cohort with prior treatment failure (accelerated‐phase [AP, n = 79] chronic myeloid leukemia [CML], blast‐phase [BP, n = 64] CML, acute lym...
Na minha lista:
| Udgivet i: | Am J Hematol |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley and Sons Inc.
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5132035/ https://ncbi.nlm.nih.gov/pubmed/26040495 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ajh.24034 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|